An intensive care chemo- or chemoimmunotherapy regimen for patients with intermediate and poor-prognosis acute lymphatic leukemia and leukemic lymphoblastic lymphosarcoma: preliminary results with 14-month median follow-up.
D000293:Adolescent; D001215:Asparaginase / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis
D004317:Doxorubicin; D001215:Asparaginase; D011241:Prednisone